Cargando…

Plasma Metabolic Disturbances in Parkinson’s Disease Patients

Plasma from patients with Parkinson’s disease (PD) is a valuable source of information indicating altered metabolites associated with the risk or progression of the disease. Neurotoxicity of dopaminergic neurons, which is triggered by aggregation of α-synuclein, is the main pathogenic feature of PD....

Descripción completa

Detalles Bibliográficos
Autores principales: Gątarek, Paulina, Sekulska-Nalewajko, Joanna, Bobrowska-Korczaka, Barbara, Pawełczyk, Małgorzata, Jastrzębski, Karol, Głąbiński, Andrzej, Kałużna-Czaplińska, Joanna
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9775245/
https://www.ncbi.nlm.nih.gov/pubmed/36551761
http://dx.doi.org/10.3390/biomedicines10123005
_version_ 1784855596728582144
author Gątarek, Paulina
Sekulska-Nalewajko, Joanna
Bobrowska-Korczaka, Barbara
Pawełczyk, Małgorzata
Jastrzębski, Karol
Głąbiński, Andrzej
Kałużna-Czaplińska, Joanna
author_facet Gątarek, Paulina
Sekulska-Nalewajko, Joanna
Bobrowska-Korczaka, Barbara
Pawełczyk, Małgorzata
Jastrzębski, Karol
Głąbiński, Andrzej
Kałużna-Czaplińska, Joanna
author_sort Gątarek, Paulina
collection PubMed
description Plasma from patients with Parkinson’s disease (PD) is a valuable source of information indicating altered metabolites associated with the risk or progression of the disease. Neurotoxicity of dopaminergic neurons, which is triggered by aggregation of α-synuclein, is the main pathogenic feature of PD. However, a growing body of scientific reports indicates that metabolic changes may precede and directly contribute to neurodegeneration. Identification and characterization of the abnormal metabolic pattern in patients’ plasma are therefore crucial for the search for potential PD biomarkers. The aims of the present study were (1) to identify metabolic alterations in plasma metabolome in subjects with PD as compared with the controls; (2) to find new potential markers, some correlations among them; (3) to identify metabolic pathways relevant to the pathophysiology of PD. Plasma samples from patients with PD (n = 25) and control group (n = 12) were collected and the gas chromatography-time-of-flight-mass spectrometry GC-TOFMS-based metabolomics approach was used to evaluate the metabolic changes based on the identified 14 metabolites with significantly altered levels using univariate and multivariate statistical analysis. The panel, including 6 metabolites (L-3-methoxytyrosine, aconitic acid, L-methionine, 13-docosenamide, hippuric acid, 9,12-octadecadienoic acid), was identified to discriminate PD from controls with the area under the curve (AUC) of 0.975, with an accuracy of 92%. We also used statistical criteria to identify the significantly altered level of metabolites. The metabolic pathways involved were associated with linoleic acid metabolism, mitochondrial electron transport chain, glycerolipid metabolism, and bile acid biosynthesis. These abnormal metabolic changes in the plasma of patients with PD were mainly related to the amino acid metabolism, TCA cycle metabolism, and mitochondrial function.
format Online
Article
Text
id pubmed-9775245
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-97752452022-12-23 Plasma Metabolic Disturbances in Parkinson’s Disease Patients Gątarek, Paulina Sekulska-Nalewajko, Joanna Bobrowska-Korczaka, Barbara Pawełczyk, Małgorzata Jastrzębski, Karol Głąbiński, Andrzej Kałużna-Czaplińska, Joanna Biomedicines Article Plasma from patients with Parkinson’s disease (PD) is a valuable source of information indicating altered metabolites associated with the risk or progression of the disease. Neurotoxicity of dopaminergic neurons, which is triggered by aggregation of α-synuclein, is the main pathogenic feature of PD. However, a growing body of scientific reports indicates that metabolic changes may precede and directly contribute to neurodegeneration. Identification and characterization of the abnormal metabolic pattern in patients’ plasma are therefore crucial for the search for potential PD biomarkers. The aims of the present study were (1) to identify metabolic alterations in plasma metabolome in subjects with PD as compared with the controls; (2) to find new potential markers, some correlations among them; (3) to identify metabolic pathways relevant to the pathophysiology of PD. Plasma samples from patients with PD (n = 25) and control group (n = 12) were collected and the gas chromatography-time-of-flight-mass spectrometry GC-TOFMS-based metabolomics approach was used to evaluate the metabolic changes based on the identified 14 metabolites with significantly altered levels using univariate and multivariate statistical analysis. The panel, including 6 metabolites (L-3-methoxytyrosine, aconitic acid, L-methionine, 13-docosenamide, hippuric acid, 9,12-octadecadienoic acid), was identified to discriminate PD from controls with the area under the curve (AUC) of 0.975, with an accuracy of 92%. We also used statistical criteria to identify the significantly altered level of metabolites. The metabolic pathways involved were associated with linoleic acid metabolism, mitochondrial electron transport chain, glycerolipid metabolism, and bile acid biosynthesis. These abnormal metabolic changes in the plasma of patients with PD were mainly related to the amino acid metabolism, TCA cycle metabolism, and mitochondrial function. MDPI 2022-11-22 /pmc/articles/PMC9775245/ /pubmed/36551761 http://dx.doi.org/10.3390/biomedicines10123005 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Gątarek, Paulina
Sekulska-Nalewajko, Joanna
Bobrowska-Korczaka, Barbara
Pawełczyk, Małgorzata
Jastrzębski, Karol
Głąbiński, Andrzej
Kałużna-Czaplińska, Joanna
Plasma Metabolic Disturbances in Parkinson’s Disease Patients
title Plasma Metabolic Disturbances in Parkinson’s Disease Patients
title_full Plasma Metabolic Disturbances in Parkinson’s Disease Patients
title_fullStr Plasma Metabolic Disturbances in Parkinson’s Disease Patients
title_full_unstemmed Plasma Metabolic Disturbances in Parkinson’s Disease Patients
title_short Plasma Metabolic Disturbances in Parkinson’s Disease Patients
title_sort plasma metabolic disturbances in parkinson’s disease patients
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9775245/
https://www.ncbi.nlm.nih.gov/pubmed/36551761
http://dx.doi.org/10.3390/biomedicines10123005
work_keys_str_mv AT gatarekpaulina plasmametabolicdisturbancesinparkinsonsdiseasepatients
AT sekulskanalewajkojoanna plasmametabolicdisturbancesinparkinsonsdiseasepatients
AT bobrowskakorczakabarbara plasmametabolicdisturbancesinparkinsonsdiseasepatients
AT pawełczykmałgorzata plasmametabolicdisturbancesinparkinsonsdiseasepatients
AT jastrzebskikarol plasmametabolicdisturbancesinparkinsonsdiseasepatients
AT głabinskiandrzej plasmametabolicdisturbancesinparkinsonsdiseasepatients
AT kałuznaczaplinskajoanna plasmametabolicdisturbancesinparkinsonsdiseasepatients